Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Dec 15, 2024; 16(12): 4579-4596
Published online Dec 15, 2024. doi: 10.4251/wjgo.v16.i12.4579
Published online Dec 15, 2024. doi: 10.4251/wjgo.v16.i12.4579
Variables | N (1167) | Before PSM | P value | N (656) | After PSM | P value | |||
GPR ≤ 0.2 (n = 381) | GPR > 0.2 (n = 786) | GPR ≤ 0.2 (n = 328) | GPR > 0.2 (n = 328) | ||||||
Sex | Male | 985 | 278 | 707 | < 0.001 | 533 | 266 | 267 | 1 |
Female | 182 | 103 | 79 | 123 | 62 | 61 | |||
Age (years) | ≤ 50 | 654 | 229 | 425 | 0.059 | 377 | 196 | 181 | 0.269 |
> 50 | 513 | 152 | 361 | 279 | 132 | 147 | |||
Body mass index | > 24 | 354 | 124 | 230 | 0.282 | 205 | 107 | 98 | 0.5 |
≤ 24 | 813 | 257 | 556 | 451 | 221 | 230 | |||
Smoking | Yes | 407 | 100 | 307 | < 0.001 | 190 | 97 | 93 | 0.796 |
No | 760 | 281 | 479 | 466 | 231 | 235 | |||
Drinking | Yes | 386 | 89 | 297 | < 0.001 | 179 | 87 | 92 | 0.726 |
No | 781 | 292 | 489 | 477 | 241 | 236 | |||
Diabetes mellitus | Yes | 59 | 15 | 44 | 0.284 | 33 | 15 | 18 | 0.721 |
No | 1108 | 366 | 742 | 623 | 313 | 310 | |||
Hypertension | Yes | 114 | 38 | 76 | 0.953 | 67 | 33 | 34 | 1 |
No | 1053 | 343 | 710 | 589 | 295 | 294 | |||
Family history of liver cancer | Yes | 128 | 41 | 87 | 0.954 | 72 | 39 | 33 | 0.532 |
No | 1039 | 340 | 699 | 584 | 289 | 295 | |||
Liver flukes | Yes | 221 | 53 | 168 | 0.003 | 112 | 51 | 61 | 0.35 |
No | 946 | 328 | 618 | 544 | 277 | 267 | |||
Cirrhosis | Yes | 587 | 158 | 429 | < 0.001 | 280 | 145 | 135 | 0.477 |
No | 580 | 223 | 357 | 376 | 183 | 193 | |||
Serum alpha-fetoprotein (ng/mL) | ≥ 200 | 440 | 164 | 276 | 0.011 | 246 | 139 | 107 | 0.012 |
< 200 | 727 | 217 | 510 | 410 | 189 | 221 | |||
Child-Pugh | A | 1151 | 378 | 773 | 0.355 | 649 | 325 | 324 | 1 |
B | 16 | 3 | 13 | 7 | 3 | 4 | |||
Barcelona Clinic Liver Cancer stage | 0 | 172 | 65 | 107 | 0.142 | 103 | 53 | 50 | 0.83 |
A | 995 | 316 | 679 | 553 | 275 | 278 | |||
Total bilirubin (μmol/L) | > 20.5 | 128 | 31 | 97 | 0.04 | 73 | 28 | 45 | 0.047 |
≤ 20.5 | 1039 | 350 | 689 | 583 | 300 | 283 | |||
Albumin (g/L) | > 40 | 534 | 223 | 311 | < 0.001 | 354 | 184 | 170 | 0.309 |
≤ 40 | 633 | 158 | 475 | 302 | 144 | 158 | |||
Gamma-glutamyl transpeptidase (U/L) | > 50 | 557 | 18 | 539 | < 0.001 | 221 | 18 | 203 | < 0.001 |
≤ 50 | 610 | 363 | 247 | 435 | 310 | 125 | |||
Hepatitis B virus DNA (IU/mL) | > 1000 | 521 | 143 | 378 | 0.001 | 277 | 126 | 151 | 0.058 |
≤ 1000 | 646 | 238 | 408 | 379 | 202 | 177 | |||
HBeAg status | - | 299 | 619 | 918 | 0.914 | 259 | 252 | 511 | 0.510 |
+ | 82 | 167 | 249 | 69 | 76 | 145 | |||
Antiviral therapy | No | 265 | 521 | 786 | 0.264 | 233 | 221 | 454 | 0.310 |
Yes | 116 | 265 | 381 | 95 | 107 | 202 | |||
Surgical margin (cm) | < 2 | 169 | 308 | 477 | 0.092 | 146 | 127 | 273 | 0.132 |
≥ 2 | 212 | 478 | 690 | 182 | 201 | 383 | |||
Tumor size (cm) | > 5 | 444 | 113 | 331 | < 0.001 | 208 | 103 | 105 | 0.933 |
≤ 5 | 723 | 268 | 455 | 448 | 225 | 223 | |||
Microvascular invasion | Yes | 301 | 86 | 215 | 0.093 | 152 | 79 | 73 | 0.644 |
No | 866 | 295 | 571 | 504 | 249 | 255 | |||
Infiltrative growth | Yes | 438 | 166 | 272 | 0.004 | 270 | 137 | 133 | 0.812 |
No | 729 | 215 | 514 | 386 | 191 | 195 |
Variables | Before propensity matching | After propensity matching | ||||||
Uni-HR (95%CI) | P value | Multi-HR (95%CI) | P value | Uni-HR (95%CI) | P value | Multi-HR (95%CI) | P value | |
Sex (male/female) | 1.44 (1.01-2.05) | 0.043 | 1.3 (0.9-1.87) | 0.159 | 1.22 (0.79-1.87) | 0.364 | ||
Age (years) (> 50/≤ 50) | 1.02 (0.81-1.29) | 0.85 | 0.86 (0.63-1.19) | 0.362 | ||||
Body mass index (> 24/≤ 24) | 1.16 (0.9-1.49) | 0.255 | 1.25 (0.88-1.79) | 0.218 | ||||
Smoking (yes/no) | 1.05 (0.83-1.34) | 0.672 | 1.04 (0.74-1.48) | 0.81 | ||||
Drinking (yes/no) | 0.9 (0.7-1.15) | 0.412 | 0.85 (0.59-1.23) | 0.388 | ||||
Diabetes mellitus (yes/no) | 0.75 (0.4-1.41) | 0.372 | 0.46 (0.15-1.45) | 0.186 | ||||
Hypertension (yes/no) | 0.82 (0.54-1.24) | 0.345 | 0.66 (0.36-1.23) | 0.192 | ||||
Family cases (yes/no) | 0.79 (0.53-1.17) | 0.234 | 0.61 (0.34-1.1) | 0.098 | ||||
Liver flukes (yes/no) | 0.88 (0.65-1.19) | 0.392 | 0.75 (0.47-1.18) | 0.214 | ||||
Cirrhosis (yes/no) | 1.21 (0.96-1.53) | 0.1 | 1.24 (0.9-1.71) | 0.18 | ||||
Child-Pugh (B/A) | 2.16 (1.07-4.36) | 0.032 | 1.78 (0.87-3.63) | 0.115 | 1.34 (0.33-5.42) | 0.679 | ||
Barcelona Clinic Liver Cancer stage (A/0) | 1.93 (1.31-2.83) | < 0.001 | 1.51 (1-2.26) | 0.048 | 2.03 (1.19-3.45) | 0.009 | 1.64 (0.94-2.86) | 0.082 |
Total bilirubin (μmol/L) (> 20.5/≤ 20.5) | 0.85 (0.6-1.21) | 0.37 | 0.9 (0.55-1.45) | 0.651 | ||||
Albumin (g/L) (> 40/≤ 40) | 1.35 (1.07-1.71) | 0.012 | 1.16 (0.91-1.48) | 0.229 | 1.2 (0.87-1.65) | 0.26 | ||
Alpha-fetoprotein (ng/mL) (≥ 200/< 200) | 1.38 (1.09-1.74) | 0.006 | 1.35 (1.06-1.72) | 0.013 | 1.37 (0.99-1.89) | 0.055 | ||
Hepatitis B virus DNA (IU/mL) (> 1000/≤ 1000) | 0.73 (0.58-0.92) | 0.008 | 0.83 (0.66-1.05) | 0.123 | 0.72 (0.52-0.99) | 0.042 | 0.82 (0.59-1.12) | 0.213 |
Tumor size (cm) (≤ 5/> 5) | 0.57 (0.46-0.72) | < 0.001 | 0.74 (0.57-0.95) | 0.019 | 0.6 (0.43-0.82) | 0.002 | 0.66 (0.48-0.93) | 0.017 |
Microvascular invasion (yes/no) | 1.55 (1.21-1.99) | < 0.001 | 1.19 (0.92-1.55) | 0.186 | 1.2 (0.83-1.74) | 0.322 | ||
Infiltrative growth (yes/no) | 1.29 (1.02-1.63) | 0.032 | 1.35 (1.06-1.7) | 0.014 | 1.2 (0.87-1.65) | 0.272 | ||
Gamma-glutamyl transpeptidase-to-platelet ratio (≤ 0.2/> 0.2) | 0.48 (0.36-0.64) | < 0.001 | 0.52 (0.39-0.69) | < 0.001 | 0.49 (0.35-0.69) | < 0.001 | 0.5 (0.36-0.7) | < 0.001 |
Variables | Before propensity matching | After propensity matching | ||||||
Uni-HR (95%CI) | P value | Multi-HR (95%CI) | P value | Uni-HR (95%CI) | P value | Multi-HR (95%CI) | P value | |
Sex (male/female) | 1.32 (1.03-1.69) | 0.028 | 1.19 (0.92-1.54) | 0.176 | 1.09 (0.8-1.49) | 0.574 | ||
Age (years) (> 50/≤ 50) | 1.03 (0.87-1.22) | 0.756 | 0.93 (0.73-1.19) | 0.575 | ||||
Body mass index (> 24/≤ 24) | 1.13 (0.94-1.36) | 0.185 | 1 (0.77-1.29) | 0.989 | ||||
Smoking (yes/no) | 1.11 (0.93-1.32) | 0.244 | 1.01 (0.78-1.31) | 0.93 | ||||
Drinking (yes/no) | 1 (0.84-1.2) | 0.972 | 0.85 (0.64-1.11) | 0.23 | ||||
Diabetes mellitus (yes/no) | 1.4 (0.98-2) | 0.067 | 1.22 (0.71-2.1) | 0.461 | ||||
Hypertension (yes/no) | 0.81 (0.6-1.09) | 0.165 | 0.83 (0.54-1.26) | 0.38 | ||||
Family cases (yes/no) | 0.89 (0.68-1.16) | 0.384 | 0.76 (0.51-1.14) | 0.192 | ||||
Liver flukes (yes/no) | 1.14 (0.93-1.4) | 0.204 | 1.01 (0.74-1.38) | 0.945 | ||||
Cirrhosis (yes/no) | 1.27 (1.08-1.5) | 0.005 | 1.25 (1.05-1.49) | 0.012 | 1.3 (1.03-1.65) | 0.03 | 1.33 (1.04-1.68) | 0.021 |
Child-Pugh (B/A) | 1.08 (0.54-2.18) | 0.823 | 1.01 (0.32-3.14) | 0.99 | ||||
Barcelona Clinic Liver Cancer stage (A/0) | 1.4 (1.09-1.8) | 0.008 | 1.14 (0.87-1.49) | 0.348 | 1.39 (0.98-1.97) | 0.061 | ||
Total bilirubin (μmol/L) (> 20.5/≤ 20.5) | 0.87 (0.67-1.13) | 0.292 | 0.85 (0.6-1.22) | 0.386 | ||||
Albumin (g/L) (> 40/≤ 40) | 1.36 (1.15-1.61) | < 0.001 | 1.17 (0.98-1.4) | 0.084 | 1.21 (0.96-1.54) | 0.112 | ||
Alpha-fetoprotein (ng/mL) (≥ 200/< 200) | 1.31 (1.1-1.55) | 0.002 | 1.29 (1.08-1.54) | 0.005 | 1.22 (0.96-1.55) | 0.111 | ||
Hepatitis B virus DNA (IU/mL) (> 1000/≤ 1000) | 0.8 (0.68-0.95) | 0.009 | 0.9 (0.76-1.06) | 0.214 | 0.76 (0.6-0.96) | 0.023 | 0.8 (0.63-1.02) | 0.067 |
Tumor size (cm) (≤ 5/> 5) | 0.6 (0.51-0.71) | < 0.001 | 0.67 (0.55-0.81) | < 0.001 | 0.79 (0.62-1.02) | 0.07 | ||
Microvascular invasion (yes/no) | 1.4 (1.16-1.68) | < 0.001 | 1.1 (0.9-1.33) | 0.359 | 1.18 (0.9-1.56) | 0.233 | ||
Infiltrative growth (yes/no) | 1.24 (1.05-1.47) | 0.013 | 1.28 (1.08-1.53) | 0.005 | 1.24 (0.97-1.57) | 0.082 | ||
Gamma-glutamyl transpeptidase-to-platelet ratio (≤ 0.2/> 0.2) | 0.49 (0.4-0.6) | < 0.001 | 0.53 (0.43-0.65) | < 0.001 | 0.56 (0.44-0.71) | < 0.001 | 0.57 (0.44-0.73) | < 0.001 |
Variables | Before propensity matching | After propensity matching | ||||||
OS-HR (95%CI) | P value | RFS-HR (95%CI) | P value | OS-HR (95%CI) | P value | RFS-HR (95%CI) | P value | |
As continuous | 1.12 (1.04-1.20) | 0.002 | 1.11 (1.06-1.17) | < 0.001 | 1.29 (1.18-1.42) | < 0.001 | 1.20 (1.11-1.31) | < 0.001 |
By GPR cut-off | ||||||||
GPR ≤ 0.2 | ||||||||
GPR > 0.2 | 2.07 (1.56-2.74) | < 0.001 | 2.05 (1.68-2.51) | < 0.001 | 2.04 (1.46-2.84) | < 0.001 | 1.79 (1.40-2.28) | < 0.001 |
By GPR tercile | ||||||||
Bottom (≤ 0.2) | ||||||||
Middle (> 0.2, ≤ 0.6) | 1.81 (1.35-2.44) | < 0.001 | 1.85 (1.50-2.29) | < 0.001 | 1.52 (1.08-2.14) | 0.017 | 1.69 (1.25-2.17) | < 0.001 |
Top (> 0.6) | 2.74 (1.98-3.81) | < 0.001 | 2.60 (2.04-3.31) | < 0.001 | 2.33 (1.60-3.39) | < 0.001 | 2.35 (1.77-3.13) | < 0.001 |
P for trend1 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | ||||
By interquartile | ||||||||
Q1 | ||||||||
Q2 | 1.42 (0.98-2.06) | 0.061 | 1.43 (1.10-1.86) | < 0.001 | 0.75 (0.43-1.28) | 0.288 | 0.88 (0.60-1.29) | 0.514 |
Q3 | 1.72 (1.20-2.46) | 0.003 | 1.74 (1.35-2.24) | < 0.001 | 1.45 (0.90-2.34) | 0.125 | 1.58 (1.12-2.23) | 0.009 |
Q4 | 2.34 (1.66-3.29) | < 0.001 | 2.29 (1.79-2.93) | < 0.001 | 2.08 (1.33-3.24) | 0.001 | 1.79 (1.27-2.51) | 0.001 |
P for trend1 | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
- Citation: Yang CK, Wei ZL, Shen XQ, Jia YX, Wu QY, Wei YG, Su H, Qin W, Liao XW, Zhu GZ, Peng T. Prognostic utility of gamma-glutamyl transpeptidase to platelet ratio in patients with solitary hepatitis B virus-related hepatocellular carcinoma after hepatectomy. World J Gastrointest Oncol 2024; 16(12): 4579-4596
- URL: https://www.wjgnet.com/1948-5204/full/v16/i12/4579.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i12.4579